Therapy for severe interstitial lung disease in systemic sclerosis. a retrospective study

Arthritis & Rheumatism

Volumn 37, Issue 9, 1994, Pages 1290-1296

  Steen, Virginia D ^a   Lanz, James K ^a   Conte, Claudia ^a   Owens, Gregory R ^a   Medsger, Thomas A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FLUOROURACIL; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PENICILLAMINE; PREDNISONE;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; INTRAVENOUS DRUG ADMINISTRATION; LUNG FUNCTION TEST; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SYSTEMIC SCLEROSIS;

ADULT; BRONCHOALVEOLAR LAVAGE FLUID; CELL COUNT; CYCLOPHOSPHAMIDE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE AGENTS; MALE; PENICILLAMINE; PREDNISONE; PULMONARY FIBROSIS; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; VITAL CAPACITY;

EID: 0028054192     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.1780370904     Document Type: Article

References (24)

1. Severe restrictive lung disease in systemic sclerosis
2. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin‐converting enzyme (ACE) inhibitors
3. Epidemiology of rheumatic disease: systemic sclerosis
4. Structural features of interstitial lung disease in systemic sclerosis
5. Pulmonary function in progressive systemic sclerosis: comparison of CREST syndrome variant with diffuse scleroderma
6. A theory and experimental analysis of anomalies in estimation of pulmonary diffusing capacity by single breath method
7. Isolated diffusing capacity reduction in systemic sclerosis
8. The use of the Health Assessment Questionnaire (HAQ) to determine the physical disability in systemic sclerosis
9. Role of inflammation in the lung disease of systemic sclerosis: comparison with idiopathic pulmonary fibrosis
10. Interstitial lung disease: current concepts of pathogenesis, staging and therapy
11. Interstitial lung disease in scleroderma: immune complexes in sera and bronchoalveolar lavage fluid
12. Cryptogenic fibrosing alveolitis
13. D‐penicillamine therapy and interstitial lung disease in scleroderma: a long‐term followup study
14. The effect of D‐penicillamine on pulmonary findings in systemic sclerosis
15. Natural history and treated course of usual and desquamative interstitial pneumonia
16. Steroid‐responsive interstitial pulmonary disease in systemic sclerosis: monitoring by bronchoalveolar lavage
17. Evidence for chronic inflammation as a component of the interstitial lung disease associated with progressive systemic sclerosis
18. Lung involvement in sclero‐derma
19. Treatment of progressive systemic sclerosis by plasma exchange: long‐term results in 40 patients
20. Immunosuppression with chlorambucil, versus placebo, for scleroderma: results of a three‐year, parallel, randomized, double‐blind study
21. 5‐Fluorouracil in the treatment of scleroderma: a randomized, double‐blind, placebo controlled international collaborative study
22. Treatment of systemic sclerosis with recombinant interferon‐γ: a phase I/II clinical trial
23. Cyclophosphamide and low dose prednisone therapy in systemic sclerosis (scleroderma) patients with interstitial lung disease